Form 4: VYNE Therapeutics CEO Sells Shares to Cover Tax Obligations

VYNE Therapeutics CEO, David Domzalski, sold 24,536 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• David Domzalski, the President and CEO of VYNE Therapeutics, sold 24,536 shares of common stock on December 31, 2024.
• The sale was executed at a price of $3.35 per share.
• This transaction was to cover tax withholding requirements associated with the vesting of restricted stock units.
• Following the transaction, Domzalski directly owns 476,061 shares of VYNE Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of executive compensation packages, leading to similar tax-related sales.
• The sale of 24,536 shares is not unusual for a CEO of a company of this size.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

VYNE Therapeutics, David Domzalski, stock sale, insider trading, tax withholding, restricted stock units, executive compensation